TRANSCODE THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $165.95 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-04-15
- TRANSCODE THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $165.95K, a 60.73% decline from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $422.54K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $165.95K 10-K · filed 2026-04-15 |
| 2024-12-31 | $422.54K 10-K · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |